Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC), not all patients benefit. We therefore explored the impact of the presence of mutations found in cell-f...

Full description

Bibliographic Details
Main Authors: Christi M. J. Steendam, G. D. Marijn Veerman, Melinda A. Pruis, Peggy Atmodimedjo, Marthe S. Paats, Cor van der Leest, Jan H. von der Thüsen, David C. Y. Yick, Esther Oomen-de Hoop, Stijn L. W. Koolen, Winand N. M. Dinjens, Ron H. N. van Schaik, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Hendrikus Jan Dubbink, Anne-Marie C. Dingemans
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
NSCLC
EGFR
TKI
cfDNA
plasma conversion
TP53 mutation
Online Access:https://www.mdpi.com/2072-6694/12/11/3179

Internet

https://www.mdpi.com/2072-6694/12/11/3179

Similar Items